Notice of Cipher Pharmaceuticals Annual and Special Meeting of Shareholders

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, April 14 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced it will hold its Annual and Special Meeting of Shareholders on Thursday, April 22, 2010 at 4:30 p.m. ET.

    
    WHAT:     ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

    WHERE:    TORONTO BOARD OF TRADE
              1 FIRST CANADIAN PLACE
              TORONTO, ONTARIO

    WHEN:     THURSDAY, APRIL 22, 2010 AT 4:30 P.M. ET.
    

The meeting will be webcast live. To access the webcast go to:

http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2998160

Please connect at least 15 minutes prior to the start of the meeting to ensure adequate time for any software download that may be required to join the webcast.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a commercial-stage drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen(R). In addition, Cipher is developing formulations of the pain reliever tramadol (tentative FDA approval in February 2009) and the acne treatment isotretinoin (FDA approvable letter in April 2007).

Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding. For more information, please visit www.cipherpharma.com.

For further information: INVESTOR RELATIONS CONTACT: Craig Armitage, The Equicom Group Inc., [phone] ext. 278, [email protected]